血液检测的承诺与被遗忘的预算The Promise of Blood Tests and the Forgotten Budget
血液检测能提高阿尔茨海默症的诊断精度，这在 direct 层确实减少了误诊的暴力。但我们要问：诊断权的下放，是否意味着治疗资源的普惠？
在医学研究的 funding 逻辑里，一个疾病能否被“解决”，不取决于检测技术的突破，而取决于它在男性中心叙事中的优先级。回顾痛经研究与艾滋病研究之间巨大的预算鸿沟，你会发现医学界对“女性特有痛苦”的耐受度极高。阿尔茨海默症在女性中的发病率显著高于男性，这种生物墙带来的高发病率，在长期的 structural violence 下，往往被简化为“老龄化”或“自然衰退”，而非被视为一种紧迫的、需要倾斜资源的人权危机。
如果血液检测最终只是让更多女性在绝望中提前十年知道自己将失去主体性，而昂贵的药物和护理资源依然被垄断在少数经济上位者手中，那么这种“新承诺”不过是一次精准的 cultural violence——它用技术的进步掩盖了资源分配的停滞。诊断是认知入口，但生存是资源博弈。
期待的是一个 Actual 朝 Potential 走近的未来：不仅是能检测出 tau 蛋白，更是让针对女性高发疾病的专项 funding 达到一个公正的量级。
Blood tests improving Alzheimer’s diagnostic accuracy undoubtedly reduce direct violence by minimizing misdiagnosis. But the question remains: does the decentralization of diagnostic power imply the democratization of treatment resources?
In the funding logic of medical research, whether a disease is "solved" depends not on the breakthrough of detection technology, but on its priority within the masculine-centric narrative. Recalling the massive budget gap between menstrual pain research and HIV funding, it is clear that the medical establishment has a high tolerance for "female-specific suffering." Alzheimer’s occurs significantly more often in women—a biological wall—yet under long-term structural violence, this is often dismissed as mere "aging" or "natural decline" rather than an urgent human rights crisis.
If blood tests only allow more women to know a decade earlier that they will lose their subjectivity, while expensive drugs and care resources remain monopolized by the economic elite, then this "new promise" is merely a sophisticated form of cultural violence. It uses technical progress to mask the stagnation of resource distribution. Diagnosis is a cognitive entry point, but survival is a game of resource博弈.
I look for a future where Actual moves closer to Potential: not just detecting tau proteins, but ensuring that specialized funding for diseases with high female prevalence reaches a just magnitude.